Level of (s)Fas in cerebrospinal fluid in patients with multiple sclerosis

Mahović, Darija; Petravić, Damir; Zurak, Niko; Petelin, Željka; Horvat, Gordana; Alvir, Domagoj; Šupe, Svjetlana

Pregled bibliografske jedinice broj: 121608

Level of (s)Fas in cerebrospinal fluid in patients with multiple sclerosis

Mahović, Darija; Petravić, Damir; Zurak, Niko; Petelin, Željka; Horvat, Gordana; Alvir, Domagoj; Šupe, Svjetlana

Level of (s)Fas in cerebrospinal fluid in patients with multiple sclerosis // Abstracts of the 2nd Dubrovnik International Conference on Multiple Sclerosis and Continuing Education ; u: Neurologia Croatica. Supplement (ISSN 1331-5196) 52 (2003) (S1)
Dubrovnik, Hrvatska, 2003. str. 50-50 (poster, međunarodna recenzija, sažetak, znanstveni)

CROSBI ID: 121608 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Level of (s)Fas in cerebrospinal fluid in patients with multiple sclerosis

Autori
Mahović, Darija ; Petravić, Damir ; Zurak, Niko ; Petelin, Željka ; Horvat, Gordana ; Alvir, Domagoj ; Šupe, Svjetlana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 2nd Dubrovnik International Conference on Multiple Sclerosis and Continuing Education ; u: Neurologia Croatica. Supplement (ISSN 1331-5196) 52 (2003) (S1) / - , 2003, 50-50

Skup
Dubrovnik International Conference on Multiple Sclerosis and Continuing Education (2 ; 2003)

Mjesto i datum
Dubrovnik, Hrvatska, 21.05.2003. - 24.05.2003

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
(s)Fas/APO 1; apoptosis; multiple sclerosis; cerebrospinal fluid

Sažetak
The aim of the study was to assess the possible involvement of apoptosis in the pathogenesis of multiple sclerosis (MS) by measuring the level of soluble (s)Fas/APO-1 (antiapoptotic marker) in cerebrospinal fluid (CSF) of MS patients. This pilot case-control study included 12 patients with MS (mean age 40± 6 years) and 12 patients with other neurologic symptoms such as cephalea or vertigo (mean age 41± 6 years) as a control group. In the MS group, there were 8 patients with relapsing-remitting and 4 with secondary progressive MS. Patients with a history of other autoimmune, malignant or severe infectious diseases were not included in the study. The clinical status of MS patients was assessed by EDSS. The level of (s)Fas in CSF samples was determined by ELISA. Results were expressed as mean ± standard deviation. Between-group differences were determined by t-test. Values of p<0.05 were considered statistically significant. The level of soluble (s)Fas/APO-1 was lower in MS patients than in the control group (258± 71 vs. 315± 33 pg/ml, p=0.02). Study results suggested the possible contribution of apoptosis to the pathogenesis of MS.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Projekti:
0108296

Ustanove:
Medicinski fakultet, Zagreb

Profili:

Željka Petelin Gadže (autor)